Annex Advisory Services LLC Sells 9,992 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Annex Advisory Services LLC sold 9,992 shares of Medpace during Q4 (a 9.8% reduction), leaving it with 91,693 shares valued at about $51.5 million and representing roughly 0.33% of the company.
• Medpace reported a strong quarter — $4.67 EPS vs. $4.18 est. and $708.5M revenue (+32% y/y) — and set FY2026 EPS guidance of $16.68–$17.50, supporting recent investor interest.
• The company faces potential near-term pressure from multiple class-action filings covering Apr 2025–Feb 2026, and President Jesse J. Geiger sold 31,707 shares (~$14.4M), reducing his ownership by ~67.9%, which may amplify sentiment and governance scrutiny.

Annex Advisory Services LLC decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 9.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,693 shares of the company's stock after selling 9,992 shares during the period. Annex Advisory Services LLC owned about 0.33% of Medpace worth $51,499,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC lifted its position in Medpace by 24.8% during the fourth quarter. Farther Finance Advisors LLC now owns 2,129 shares of the company's stock valued at $1,196,000 after purchasing an additional 423 shares during the period. Stonehaven Wealth & Tax Solutions LLC bought a new position in Medpace during the fourth quarter valued at approximately $317,000. Transcend Capital Advisors LLC lifted its position in Medpace by 35.4% during the fourth quarter. Transcend Capital Advisors LLC now owns 1,282 shares of the company's stock valued at $720,000 after purchasing an additional 335 shares during the period. Burney Co. lifted its position in Medpace by 9.3% during the fourth quarter. Burney Co. now owns 714 shares of the company's stock valued at $401,000 after purchasing an additional 61 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in Medpace by 279.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,927 shares of the company's stock worth $2,767,000 after acquiring an additional 3,627 shares during the period. Institutional investors own 77.98% of the company's stock.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Recent fundamentals support the rally: Medpace reported a clear beat on the last quarterly report (Q: $4.67 EPS vs. $4.18 est.; revenue $708.5M, +32% y/y) and set FY2026 EPS guidance of $16.68–$17.50 — factors that improve near-term earnings visibility and likely underpin buying interest.
• Neutral Sentiment: Market commentary notes MEDP has recently outpaced the broader market, reflecting investor focus on the company's growth metrics and margins. Read More.
• Negative Sentiment: Multiple law firms have announced class actions or investor-alerts alleging securities-law violations covering purchases from April 22, 2025 to February 9, 2026; firms are soliciting plaintiffs and flagging June lead-plaintiff/filing deadlines — this creates reputational and potential financial risk (defense costs, settlements) and can pressure the stock until the litigation path clears. Examples: Read More., Read More., Read More., Read More., Read More..

Medpace Price Performance

Shares of NASDAQ MEDP opened at $520.00 on Wednesday. The firm has a fifty day moving average price of $470.19 and a 200-day moving average price of $537.96. The stock has a market cap of $14.85 billion, a PE ratio of 33.99, a price-to-earnings-growth ratio of 2.40 and a beta of 1.39. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analysts' expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company's revenue for the quarter was up 32.0% compared to the same quarter last year. During the same period in the prior year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Medpace in a research report on Tuesday, March 3rd. They issued an "outperform" rating and a $522.00 price target on the stock. BMO Capital Markets reiterated a "market perform" rating on shares of Medpace in a research report on Wednesday, February 11th. Wall Street Zen upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research report on Saturday, January 17th. Barclays upgraded shares of Medpace from an "underweight" rating to an "equal weight" rating and set a $500.00 price target on the stock in a research report on Friday, March 6th. Finally, Truist Financial decreased their price target on shares of Medpace from $555.00 to $539.00 and set a "hold" rating on the stock in a research report on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $486.67.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares of the company's stock, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.50% of the stock is currently owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.